Celgene Loses Bid To Stay Claims In Thalomid Suit

By Erin Coe (June 13, 2008, 12:00 AM EDT) -- A federal court refused Friday to stay Barr Laboratories Inc.'s antitrust cross-claims against Celgene Corp. in order to focus first on the patent issues arising from Celgene's suit to block Barr's proposed generic version of the cancer drug Thalomid....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!